Markets

Insider Trading

Hedge Funds

Retirement

Opinion

25 Most Valuable Medical Device Companies in the US

In this article, we will be taking a look at the 25 most valuable medical device companies in the US. If you are not interested in learning about the emerging trend in medical device industry, head straight to the 5 Most Valuable Medical Device Companies In The US

In the dynamic healthcare technology landscape, the United States boasts many medical device companies that play pivotal roles in advancing patient care and treatment outcomes. These companies stand as pillars of innovation, harnessing cutting-edge technology to develop life-saving devices and groundbreaking solutions. From giants in diagnostic imaging to pioneers in surgical robotics, the US’s most valuable medical device companies like Medtronic, Johnson & Johnson, and Abbott Laboratories, among others, exemplify excellence in research, development, and commercialization, driving progress in healthcare delivery across the nation and beyond. 

Emerging Trends and Projections in the Medical Device Industry 

The medical device industry in the United States and globally is experiencing significant and sustained growth. Projections indicate substantial expansion in the US market in the coming years. Fortune Business Insights forecasts robust growth, estimating that the US medical devices market will increase from $192.78 billion in 2023 to $291.04 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.1% during the forecast period.  

The MedTech (Medical Technology) market size was valued at USD 574,002.45 million in 2022 and is expected to expand at a CAGR of 6.0%. The annual US healthcare spending on medical devices is projected to reach around $300 billion to $400 billion, 5-6% of the total US healthcare spending. 

The U.S. Cluster Mapping Tool offers valuable insights into the states where the Medical Devices industry holds significant statistical importance within the US business economy. In 2020, the sector employed over 329,000 individuals and boasted an annual payroll of approximately $25.8 billion

The medical technology sector is also undergoing dynamic changes on a global scale. The global medical technology report for 2023 by EY sheds light on various crucial aspects for medtech company leaders, including financing and supply chain management.

The report underscores the industry’s commitment to research and development, with R&D investment reaching a record US$24.7 billion. However, this represents a deviation from the three-year trend of increasing R&D spending growth, reverting to historical norms in 2022. Additionally, the report notes a significant decrease in mergers and acquisitions (M&A) expenditure, indicating a sharp decline in investment towards inorganic growth strategies. 

The report states that the global medical device outsourcing market size is expected to reach $300.09 billion by 2032, growing at a CAGR of 11.14% from 2021 to 2028. The report cites cost-effectiveness, increased efficiency, and the need for specialized expertise as the key drivers of the outsourcing market’s growth. 

Furthermore, a report published by Markets and Markets indicates that the global medical device connectivity market size was valued at $2.6 billion in 2023 and is projected to reach $7.4 billion by 2028, growing at a CAGR of 21.5% from 2021 to 2028. The report highlights the increasing demand for healthcare IT solutions, rising healthcare costs, and the growing need for remote patient monitoring drive the market’s growth. 

Finally, a report by Fortune Business Insights states that the global surgical robotics market size was valued at $1.4 billion in 2018 and is expected to reach $6.8 billion by 2026, growing at a CAGR of 21.4% from 2019 to 2026. The report cites factors such as the increasing prevalence of chronic diseases, rising demand for minimally invasive surgeries, and advancements in robotic technologies as the key drivers of the market’s growth. 

Advancements and Expansion in Non-Invasive Imaging Technologies 

MRI and Ultrasound Machines are indispensable medical devices in healthcare, offering non-invasive imaging solutions for diagnosing various medical conditions. Both devices significantly enhance patient care and treatment outcomes across diverse medical specialties. The global MRI market is experiencing rapid growth, estimated at $5.2 billion in 2023 and projected to reach $6.6 billion by 2028, with a CAGR of 5.0% to 6.5%.  

Factors driving this growth include increased disease prevalence, technological advancements, and a preference for non-invasive imaging methods. Leading companies such as Siemens Healthineers, GE Healthcare, and Koninklijke Philips N.V. drive innovation to meet healthcare demands. Market segmentation provides insights, with North America, particularly the US, holding a significant market share due to robust healthcare infrastructure.  

Similarly, the global ultrasound machine market is rapidly expanding, projected to reach $11.6 billion by 2028, with a 6.3% CAGR from 2023 to 2028. Dominated by the US, the market is fueled by rising chronic diseases, emphasis on non-invasive procedures, and technological advancements.

Key players like GE Healthcare, Koninklijke Philips N.V., and Siemens AG drive innovation. Market segmentation reveals hospitals and surgical centers as the largest segment, with a growing demand for portable ultrasound devices. Future growth is anticipated, highlighting the pivotal role of both MRI and Ultrasound Machines in modern healthcare. 

A close-up view of medical devices, electrical stimulation electrodes, and batteries.

Our Methodology  

For our methodology, we have ranked the most valuable medical device companies in the US based on their market cap as of the time of writing this piece. For the accuracy of the data we relied on Yahoo Finance.

Here is our list of the 25 most valuable medical device companies in the US. 

25. NuVasive 

Market Capitalization: $2.08B 

NuVasive, based in San Diego, is a top medical device company focused on minimally invasive spine solutions. Their products include surgical instruments, implants, and software for surgical planning. In 2023, NuVasive was acquired by Globus Medical in a $3.1 billion all-stock deal. The merger is expected to create cross-selling opportunities, but NuVasive’s future performance will likely be influenced by the new ownership. 

24. Haemonetics Corporation (NYSE:HAE)

Market Capitalization: $3.675B 

Haemonetics Corporation (NYSE:HAE), based in Boston, specializes in hematology products. Founded in 1971, it operates in four segments: Plasma, Blood Center, Hospital, and Corporate. Offerings include automated plasma collection systems and donor management software. The company has about 3,034 employees. Haemonetics Corporation (NYSE:HAE) is poised for growth due to its focus on essential hematology products and solutions. 

23. Masimo Corporation (NASDAQ:MASI)

Market Capitalization: $7.117B 

Masimo Corporation (NASDAQ:MASI) is a leading US medical device company known for patient monitoring technologies. Masimo focuses on innovation, expanding into wearable health tracking and remote monitoring. Its technologies, like Masimo SET pulse oximetry, have shown superior performance in over 100 studies. Masimo Corporation (NASDAQ:MASI)’s products are utilized across hospitals, emergency services, home care, and veterinary settings. 

22. Penumbra, Inc. (NYSE:PEN)

Market Capitalization: $10.443B 

Penumbra, Inc. (NYSE:PEN), based in Alameda, California, is one the most valuable medical device companies in the US, founded in 2004. Specializing in neuro and vascular therapies, it operates globally across 100 markets. With innovative products like the Lightning Flash system, Penumbra, Inc. (NYSE:PEN) aims to improve patient care. With nearly 4,000 employees, the company focuses on research and development for future healthcare advancements. Penumbra’s financial growth, demonstrated in its Q3 2023 results, reflects its commitment to innovative technologies and global expansion efforts. 

21. Teleflex Incorporated (NYSE:TFX)

Market Capitalization: $11.798B 

Teleflex Incorporated (NYSE:TFX), founded in 1943 and headquartered in Wayne, Pennsylvania, is a leading medical device company in the US. Teleflex Incorporated (NYSE:TFX) is committed to improving health and quality of life and provides innovative and trusted medical devices. Their product range includes global single-use medical devices for critical care and surgical applications, covering vascular access, interventional, anesthesia, surgical, interventional urology, and respiratory products. 

20. Insulet Corporation (NASDAQ:PODD)

Market Capitalization: $13.338B 

Insulet Corporation (NASDAQ:PODD), a prominent US medical device company, specializes in insulin infusion systems for diabetes management. In 2023, the company reported revenue of $1.31 billion, with a growing net worth reaching $13.415 billion. With a resilient stock performance, it boasts a market cap of $13.338 billion. Insulet Corporation (NASDAQ:PODD)’s flagship product, the Omnipod Insulin Management System, is a critical innovation in continuous insulin delivery. Collaborations with pharmaceutical and biotech companies further customize solutions for specific needs. Led by President and CEO James R. Hollingshead, Insulet’s diverse board focuses on continuous innovation to meet the growing demand for diabetes management solutions. 

19. Varian Medical Systems 

Market Capitalization: $16.26B 

Varian Medical Systems, one of the most valuable medical device companies in the US, specializes in advanced technologies for cancer treatment, such as radiotherapy, radiosurgery, proton therapy, and brachytherapy. Varian has a market capitalization of $16.26 billion as of the writing of this article. For over 70 years, the company has been a pioneer in cancer-fighting technology, emphasizing innovation and a diverse portfolio for future contributions to medical treatment. 

18. Hologic, Inc. (NASDAQ:HOLX)

Market Capitalization: $17.321B 

Hologic, Inc. (NASDAQ:HOLX), headquartered in Marlborough, Massachusetts, is a leading medical technology company specializing in women’s health. It offers medical imaging systems, diagnostic products, and surgical devices for early disease diagnosis and treatment. With around 6,944 employees in 2022, Hologic, Inc. (NASDAQ:HOLX) has shown solid revenue growth, profitability, and a strong balance sheet. Noteworthy contributions include FDA approval for its Genius Digital Diagnostics System for cervical cancer screening and active involvement in COVID-19 testing.  

17. The Cooper Companies, Inc. (NASDAQ:COO)

Market Capitalization: $18.483B 

The Cooper Companies, Inc. (NASDAQ:COO) is a global medical device company with two central units: CooperVision for contact lenses and CooperSurgical for fertility and women’s health. Recently, it acquired select Cook Medical assets for about $300 million, focusing on obstetrics, gynecology surgery, and Doppler monitoring. This acquisition is expected to boost earnings. The Cooper Companies, Inc. (NASDAQ:COO) also acquired Obp Medical for about $60 million. With a workforce of over 15,000 and products sold in 130 countries, Cooper Companies is dedicated to improving women’s, babies’, and families’ health. 

16. Align technology, Inc. (NASDAQ:ALGN)

Market Capitalization: $23.648B 

Align Technology, Inc. (NASDAQ:ALGN) stands fourteenth among the valuable medical device companies in the US, known for innovative orthodontic and restorative dentistry products. Align Technology emphasizes research and development, with a Research Award Program funding $3 million in research. In 2023, it achieved milestones like serving 17 million Invisalign patients and supplying 100 thousand iTero scanner units.  

15. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Market Capitalization: $26.062B 

Zimmer Biomet Holdings, Inc. (NYSE:ZBH), based in Warsaw, Indiana, is a famous medical device company with over 90 years of innovation. Formed in 2015 through the acquisition of Biomet, it operates in 100+ countries, focusing on musculoskeletal technologies to restore mobility and improve patients’ lives. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) is dedicated to advancing patient care through digital technology, supporting diversity, equity, inclusion initiatives, and STEM education and disaster relief efforts. 

14. ResMed Inc. (NYSE:RMD)

Market Capitalization: $26.544B 

ResMed Inc. (NYSE:RMD), based in San Diego, California, is a leading medical equipment company founded in 1989 by Peter C. Farrell. It specializes in cloud-connectable devices for sleep apnea, COPD, and respiratory conditions. Recent developments include active involvement in COVID-19 response and European expansion through acquisitions. With a focus on digital health technologies, ResMed Inc. (NYSE:RMD) is well-positioned to meet the increasing demand for remote patient monitoring and telemedicine amidst growing respiratory conditions globally. 

13. West Pharmaceutical Services, Inc. (NYSE:WST)

Market Capitalization: $26.788B 

West Pharmaceutical Services, Inc. (NYSE:WST) is a global manufacturer of advanced containment and delivery systems for injectable medicines. They serve pharmaceutical and biotech companies, offering contract manufacturing services and solutions for various markets. With expertise in robotic integration, foil applications, and value-added solutions, West Pharmaceutical Services, Inc. (NYSE:WST) provides drug delivery systems and specialized packaging to enhance efficiency and safety in the pharmaceutical supply chain. 

12. DexCom, Inc. (NASDAQ:DXCM)

Market Capitalization: $45.125B 

DexCom, Inc. (NASDAQ:DXCM) is a top medical device company acclaimed for its continuous glucose monitoring (CGM) systems, revolutionizing diabetes management with real-time glucose readings. With a strong market presence and valued technological advancements, DexCom, Inc. (NASDAQ:DXCM) ranks among the US’s most valuable medical device firms. Future trends include continued innovation in CGM technology and global market expansion. Demonstrating impressive revenue growth and robust financial performance, DexCom’s CGM systems have profoundly impacted diabetes care, offering enhanced monitoring and management solutions through dedicated research and development efforts. 

11. IDEXX Laboratories, Inc. (NASDAQ:IDXX

Market Capitalization: $46.139B 

IDEXX Laboratories, Inc. (NASDAQ:IDXX), headquartered in Westbrook, Maine, is a prominent American multinational corporation founded in 1983 by David Evans Shaw. IDEXX’s innovations enhance pet, human, and livestock health, ensuring milk and water safety globally. The company reported a revenue of US$2.707 billion in 2021 and employed approximately 10,300 people. With a commitment to corporate responsibility and a focus on innovation and customer-centricity, IDEXX Laboratories, Inc. (NASDAQ:IDXX) is poised for continued growth and success in the future. 

10. Edwards Lifesciences Corporation (NYSE:EW)

Market Capitalization: $51.772B 

Edwards Lifesciences Corporation (NYSE:EW), a top medical device company, reported 11% sales growth to $1.53 billion in Q2 2023. Edwards Lifesciences Corporation (NYSE:EW) focuses on doubling the market opportunity to nearly $20 billion by 2028, particularly in Transcatheter Aortic Valve Replacement (TAVR) technology, with investments in trials and R&D for strong organic growth. 

9. Becton, Dickinson and Company (NYSE:BDX)

Market Capitalization: $69.556B 

Becton, Dickinson, and Company (NYSE:BDX), headquartered in Franklin Lakes, New Jersey, is a leading global medical technology company committed to advancing health through innovation and quality. In Q1 fiscal 2024, BD reported revenue of $4.7 billion, showing growth in various aspects of its business. The company prioritizes nurturing diverse STEM talent and upholding solid ethics and compliance standards. Becton, Dickinson, and company (NYSE:BDX) envisions its solutions advancing healthcare and improving patient and worker safety, with a focus on medical research, diagnostics, and healthcare delivery. 

8. Boston Scientific Corporation (NYSE:BSX)

Market Capitalization: $96.425B 

Boston Scientific Corporation (NYSE:BSX), another leading US medical device company, prioritizes values like innovation, global collaboration, and diversity. With 45,000 employees worldwide and a commercial presence in 130 countries, it impacts 33 million patients annually with over 16,000 products. Operating in three segments, including Cardiovascular and MedSurg, Boston Scientific Corporation (NYSE:BSX) focuses on global expansion and a differentiated product pipeline. Recent developments include the acquisition of Acotec and a significant investment in R&D. 

7. Medtronic plc (NYSE:MDT)

Market Capitalization: $112.249B 

Medtronic plc (NYSE:MDT), one of the biggest medical device companies, based in Dublin, Ireland, operates in four segments and reported net sales of $31.2 billion in fiscal year 2023. In Q2 fiscal 2024, it reported worldwide revenue of $7.984 billion, marking a 5.3% increase. The Cardiovascular segment, generating $11.6 billion in revenues, is notable for its cardiac devices like pacemakers and defibrillators. Medtronic plc (NYSE:MDT)’s future trends include

  • expanding its portfolio with new therapies,
  • focusing on innovation and product approvals, and
  • promoting STEM education initiatives. 

6. Stryker Corporation (NYSE:SYK)

Market Capitalization: $132.826B 

Stryker Corporation (NYSE:SYK), one of the biggest medical device companies, stands sixth among the most valuables medical device companies in the US and operates in the orthopedic market with three segments: Orthopaedics, MedSurg, and Neurotechnology & Spine. Positioned to benefit from growing demand driven by aging populations and healthcare advancements, Stryker Corporation (NYSE:SYK)’s focus on innovation and R&D is expected to drive future growth, impacting over 130 million patients annually in more than 75 countries. 

Click to see and continue reading the 5 Most Valuable Medical Device Companies In The US.

Suggested Articles:

Disclosure. None: The 25 Most Valuable Medical Device Companies In The US is originally published on Insider Monkey.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…